Mangalam Drugs And Organics LimitedMANGALAMCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 13 quarters of data

₹31.11

MCap ₹49 Cr

Mangalam Drugs And Organics Limited — Stock analysis & AI research Mangalam Drugs And Organics Limited — Seasonality — best & worst months Mangalam Drugs And Organics Limited — Technical setup — score, trend, support & resistance Mangalam Drugs And Organics Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹67 Cr

Sales · Mar 2026

-8.2% YoY

₹-5 Cr

Operating Profit · Mar 2026

-150.0% YoY

-7.5%

OPM % · Mar 2026

-154.7% YoY

₹-13 Cr

Net Profit · Mar 2026

₹-8.25

EPS · Mar 2026

-9266.7% YoY

📝 Mangalam Drugs And Organics Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Mangalam Drugs And Organics Limited reported revenue of ₹67 crore for the quarter ended March 2026 (Q4 FY26), down 8.2% from ₹73 crore in the same quarter last year, and up 15.5% sequentially over the December 2025 quarter.

The company reported a net loss of ₹13 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-8.25.

Operating profit stood at ₹-5 crore — an operating margin (OPM) of -7.5%, compared with 13.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Mangalam Drugs And Organics Limited posted revenue of ₹232 crore, a decline of 27.3% over FY25, with a net loss of ₹44 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹232 crore with a net loss of ₹44 crore.

Valuation snapshot

At the current price of ₹31.11, MANGALAM has a market capitalisation of ₹49 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 0.11%, public shareholders 64.24% of Mangalam Drugs And Organics Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹49 Cr

Current Price ?

₹31.1

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

0.48

P/S ?

0.21

P/FCF ?

-6.16

Enterprise Value ?

₹154 Cr

EV/EBITDA ?

-10.28

PEG ?

N/A

Earnings Yield ?

-21.4%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹232 Cr

OPM ?

-6.5%

Profit after tax (TTM) ?

₹-44 Cr

EPS (TTM) ?

₹-27.80

ROCE ?

-14.0%

ROE ?

-42.7%

ROA ?

-14.3%

Growth

Sales — latest qtr ?

₹67 Cr

PAT — latest qtr ?

₹-13 Cr

YoY qtr sales growth ?

-8.2%

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

-15%

Sales growth (5y) ?

-9%

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹105 Cr

Debt to Equity ?

1.02

Interest Coverage ?

-2.1

Current Ratio ?

N/A

Ownership

Promoter holding ?

35.65%

Change in promoter holding ?

-14.65%

Pledged percentage ?

N/A

Market

Return 3 months ?

12.8%

Return 6 months ?

4.1%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	91	87	82	97	102	77	80	89	73	57	50	58	67	-8.2%	+15.5%
Operating Profit	0	-3	2	7	12	8	9	9	10	-5	-3	-2	-5	-150.0%	-150.0%
Other Income	0	0	0	0	0	0	0	0	0	0	0	0	0	—	—
Interest	3	3	3	3	4	4	4	3	4	4	5	4	3	-25.0%	-25.0%
Depreciation	3	3	4	4	4	4	4	4	5	4	5	4	5	+0.0%	+25.0%
Profit Before Tax	-6	-10	-5	0	4	1	1	1	2	-13	-12	-10	-13	-750.0%	-30.0%
Net Profit	-4	-10	-4	0	4	3	3	1	0	-14	-7	-10	-13	—	-30.0%
EPS	-2.77	-6.03	-2.25	0.32	2.24	1.69	1.70	0.88	0.09	-8.67	-4.58	-6.18	-8.25	-9266.7%	-33.5%
OPM %	0.0%	-3.4%	2.4%	7.2%	11.8%	10.4%	11.2%	10.1%	13.7%	-8.8%	-6.0%	-3.4%	-7.5%	-154.7%	-120.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹319 Cr	₹232 Cr	₹232 Cr	-27.3%
Operating Profit	₹36 Cr	₹-15 Cr	₹-15 Cr	-141.7%
OPM %	11.29%	-6.47%	-6.47%	-157.3%
NPM %	2.19%	-18.97%	-18.97%	-966.2%
Other Income	₹0 Cr	₹0 Cr	₹0 Cr	—
Depreciation	₹17 Cr	₹18 Cr	₹18 Cr	+5.9%
Interest	₹15 Cr	₹16 Cr	₹16 Cr	+6.7%
EBIT	₹19 Cr	₹-33 Cr	₹-33 Cr	-273.7%
PBT	₹5 Cr	₹-48 Cr	₹-48 Cr	-1060.0%
Tax	—	—	—	—
Net Profit	₹7 Cr	₹-44 Cr	₹-44 Cr	-728.6%
EPS	₹4.36	₹-27.68	₹-27.68	-734.9%
Material Cost	—	—	—	—
Employee Cost	—	—	—	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	16	16	16	16	+0.0%
Reserves	136	127	133	87	-34.6%
Borrowings	89	107	96	105	+9.4%
Other Liabilities	117	108	114	99	-13.2%
Total Liabilities	358	357	359	308	-14.2%
Fixed Assets	142	147	156	152	-2.6%
CWIP	9	8	3	0	-100.0%
Investments	0	0	0	0	—
Other Assets	206	202	201	156	-22.4%
Total Assets	358	357	359	308	-14.2%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	38	12	43	4	-90.7%
Cash from Investing Activity	-22	-18	-19	-12	+36.8%
Cash from Financing Activity	-17	6	-22	6	+127.3%
Net Cash Flow	-1	-0	2	-2	-200.0%
Free Cash Flow	16	-6	23	-8	-134.8%
CFO/OP	148%	71%	119%	-30%	-125.2%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	46	28	45	63	+40.0%
Inventory Days	200	185	303	239	-21.1%
Days Payable	139	124	199	160	-19.6%
Cash Conversion Cycle	107	88	148	142	-4.1%
Working Capital Days	38	18	13	-54	-515.4%
ROCE %	6%	1%	8%	-14%	-275.0%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	50.30%	50.30%	35.64%	35.65%	35.65%	+0.0%
FIIs	0.53%	0.11%	0.13%	0.32%	0.11%	-65.6%
Public	49.16%	49.57%	64.22%	64.03%	64.24%	+0.3%
No. of Shareholders	19,728	19,881	21,227	25,140	23,991	-4.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	MANGALAM Mangalam Drugs	₹34.01	54	—	232	-44	-6.5%	-19.0%	-27.3%	-728.6%	-8.2%	—

❓ Frequently asked questions

What was Mangalam Drugs And Organics Limited's revenue in Q4 FY26?

What was Mangalam Drugs And Organics Limited's net profit in Q4 FY26?